# Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

> **NCT07272837** · — · RECRUITING · sponsor: **University of Alberta** · enrollment: 50 (estimated)

## Conditions studied

- Type 2 Diabetes
- Obesity
- Semaglutide
- GLP-1
- Diabetes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07272837
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-14
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-04-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07272837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07272837, "Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07272837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*